Despite substantial share price declines, these brand-name dividend stocks aren't yield traps.
News & Analysis: Bristol-Myers Squibb
Could the big pharma stock's short-term pain turn into long-term gain for patient investors?
Bristol-Myers Squibb and Celgene made a deal to sell a blockbuster drug to Amgen, and Disney and Target are forming a retail collaboration.
Here's who wins the most from the sale of Otezla.
Cancer is one of the toughest diseases to fight, and these companies are playing a great role in helping people combat it.
Each of these healthcare companies takes a different approach to fighting cancer, but all have what it takes to be long-term winners in your portfolio.
These five-star medicines should continue to push the industry higher in the next decade, despite the political blowback surrounding U.S. prescription drug prices.
These three businesses are poised to profit from the war on cancer.
BMY earnings call for the period ending June 30, 2019.
The big pharma company had good news and bad news. But the good news outweighed the bad.